Ken Griffin Bristol Myers Squibb CO Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Citadel Advisors LLC holds 2,927,800 shares of BMY stock, worth $136 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,927,800
Previous 3,568,200
17.95%
Holding current value
$136 Million
Previous $218 Million
37.72%
% of portfolio
0.02%
Previous 0.04%
Shares
32 transactions
Others Institutions Holding BMY
# of Institutions
2,670Shares Held
1.64BCall Options Held
22.4MPut Options Held
25.4M-
Vanguard Group Inc Valley Forge, PA195MShares$9.07 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.39 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY108MShares$5.03 Billion0.52% of portfolio
-
State Street Corp Boston, MA94.7MShares$4.41 Billion0.17% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA70.8MShares$3.3 Billion0.59% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...